← All trials
NCT00458276
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 1, 2007
- Primary completion
- Feb 1, 2008
- Completion date
- Mar 1, 2008
- First posted
- —
- Last posted
- —
- Enrollment
- 274
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- ActelionLead sponsor
- Stanford UniversityStudy chair
- Yeshiva UniversityStudy chair
- University of MontrealStudy chair
- University of PaviaStudy chair
- University of ViennaStudy chair
- Papworth Hospital NHS Foundation TrustStudy chair
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.